Evonile Pharma Posts Q2 Loss Amid Structural Transition

Revenue for the quarter stood at Rs 560.5 million, while net loss reached Rs 775.4 million.

Reader Takeaway: Exceptional restructuring charges drove losses; investors should monitor how management stabilizes core revenue after ownership change.

What just happened

Evonile Pharma Limited, formerly Novartis India, released its financial results for the quarter ending September 30, 2026. The company reported a net loss of Rs 775.4 million, a significant reversal from the Rs 242.2 million profit reported in the same quarter last year. Revenue from operations dropped to Rs 560.5 million, down from Rs 903.3 million in the corresponding period of the previous fiscal year.

Why this matters

The financial results capture a volatile transition period for the company. The bottom line was heavily impacted by exceptional items totaling Rs 682.6 million. These charges primarily stem from the termination of inventory purchase arrangements (Rs 610 million) and the write-off of import licenses (Rs 72.6 million). These one-time costs are directly tied to the strategic pivot following the July 2026 change in control.

The backstory

On July 29, 2026, the company underwent a major ownership shift, with Waerise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners acquiring the firm. Following this acquisition, the company officially rebranded from Novartis India Limited to Evonile Pharma Limited on October 1, 2026. Simultaneously, the company terminated an agreement with a major customer in August 2026, which has negatively impacted its established medicine brand revenues.

Risks to watch

The primary risk is the company's ability to return to profitability. While the exceptional items are one-time costs, the contraction in core revenue indicates a challenging path ahead. The company currently holds Rs 800 million in debt, and shareholders should monitor whether the new management can secure new revenue streams to replace those lost during the restructuring.

What to track next

Investors should look for management commentary on business strategy in upcoming quarters, specifically focusing on operating margin recovery and efforts to stabilize the pharmaceutical business segment. The company has confirmed it currently operates within a single 'Pharmaceutical Business' segment.